HEALTH● LOWSep 13 · Sep 13, 2026, 5:23 PM
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
Seeking Alpha Tech · global
A clinical trial shows Summit's drug, ivonescimab, reduced the risk of death by 27% compared to Keytruda in lung cancer patients. This represents a potentially important advancement in lung cancer treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH43m agoNCDs fastest-growing disease burden in Nigeria — OfficialPremium TimesHEALTH58m agoFG ‘revitalises’ 4,434 PHCs, expands access to quality healthcare servicesPremium TimesHEALTH1h agoProbiotic cuts risk of respiratory infections in formula-fed babiesNew ScientistHEALTH1h agoCleft lip and palate and other craniofacial surgery for kids isn’t cosmetic, it’s lifesavingThe Hill